Oncotarget

Clinical Research Papers:

Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer

Yushui Ma _, Likun Hou, Fei Yu, Gaixia Lu, Shanshan Qin, Ruting Xie, Huiqiong Yang, Tingmiao Wu, Pei Luo, Li Chai, Zhongwei Lv, Xiaodong Peng, Da Fu and Da Fu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:18417-18423. https://doi.org/10.18632/oncotarget.12813

Metrics: PDF 1386 views  |   HTML 1255 views  |   ?  


Abstract

Yushui Ma1,2,*, Likun Hou3,*, Fei Yu1,*, Gaixia Lu1, Shanshan Qin1, Ruting Xie4, Huiqiong Yang4, Tingmiao Wu1, Pei Luo1, Li Chai1, Zhongwei Lv1, Xiaodong Peng5, Chunyan Wu3 and Da Fu6

1 Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

2 Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China

3 Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

4 Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

5 Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China

6 Central Laboratory for Medical Research, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China

* These authors have contributed equally to this work

Correspondence to:

Xiaodong Peng, email:

Chunyan Wu, email:

Da Fu, email:

Keywords: carboplatin; hyponatremia; hypokalemia; dehydration; FDA adverse event reporting system

Received: May 01, 2016 Accepted: October 14, 2016 Published: October 21, 2016

Abstract

To clarify the association between carboplatin and electrolyte abnormality, a pooled-analysis was performed with the adverse event reports of non-small cell lung cancer patients. A total of 19901 adverse events were retrieved from the FDA Adverse Event Reporting System (FAERS). Pooled reporting odds ratios (RORs) and 95% CIs suggested that carboplatin was significantly associated with hyponatremia (pooled ROR = 1.57, 95% CI 1.18–2.09, P = 1.99×10-3) and hypokalemia (pooled ROR = 2.37, 95% CI 1.80–3.10, P = 5.24×10-10) as compared to other therapies. In addition, we found that dehydration was frequently concurrent with carboplatin therapy (pooled ROR = 2.01, 95% CI 1.52–2.66, P = 8.37×10-7), which may prompt excessive water ingestion and decrease serum electrolyte concentrations. This information has not been mentioned in the FDA-approved drug label and could help explain the physiological mechanism of carboplatin-induced electrolyte abnormality. In conclusion, the above results will facilitate clinical management and prompt intervention of life-threatening electrolyte imbalance in the course of cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12813